Cipla launches 'ViraGen' RT-PCR test
image for illustrative purpose
New Delhi Cipla Limited on Thursday announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit 'ViraGen for Covid-19 in India, in partnership with Ubio Biotechnology Systems Pvt Ltd.
ViraGen is Cipla's third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6 per cent and the specificity of 98.8 per cent as compared to a standard ICMR test.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of Covid-19.
